10/20/2026
Today is World Osteoporosis Day.
One in three women over 50 will experience an osteoporosis-related fracture in their lifetime. Most of the bone protection conversation happens after menopause. Most of the bone loss begins in perimenopause.
Estrogen is the primary regulator of bone turnover in women. It maintains equilibrium between bone resorption and formation by modulating osteoblast survival and osteoclast activity. When estrogen declines, resorption accelerates. A 2025 scoping review in Frontiers in Reproductive Health found that menopausal hormone therapy reduces bone resorption and, in combination with resistance exercise, supports bone mineral density through complementary and additive mechanisms (Alferaih et al., Front Reprod Health, 2025 — https://doi.org/10.3389/frph.2025.1542746).
Timing matters. The protective effect of hormone therapy on bone density is most pronounced when initiated closer to the onset of menopause, not years later. Lower-dose transdermal formulations can conserve bone while carrying a more favorable cardiovascular and VTE risk profile. Dose adequacy, however, is individual and requires lab monitoring rather than default assumptions (Stevenson et al., 2023 — https://doi.org/10.1177/20533691221139902).
At RxFormulations, we compound hormone therapy to the individual dose a prescriber determines is adequate for that patient. This is where compounding adds clinical value that commercial fixed-dose products cannot.
Comment 𝗖𝗢𝗡𝗦𝗨𝗟𝗧 to connect.
📍 RxFormulations | Mesa, AZ | 480-854-3100